key: cord-0903813-lymnkl97 authors: Dursun, Polat; Dervisoglu, Haluk; Daggez, Mine; Turan, Taner; Kiliç, Fatih; Tekin, Özlem M.; Üreyen, Işin; Toptaş, Tayfun; Demirayak, Gökhan; Önder, Ayşe B.; Çelik, Çetin; Bayramoğlu, Denizhan; Guzel, Ahmet B.; Arioz, Dagistan T.; Bilir, Filiz; Ozdemir, Isa A.; Tasci, Tolga; Karalok, Alper; Karateke, Ateş title: Performing gynecologic cancer surgery during the COVID‐19 pandemic in Turkey: A multicenter retrospective observational study date: 2020-08-11 journal: Int J Gynaecol Obstet DOI: 10.1002/ijgo.13296 sha: cda1d30059716145d86fe217c5f4748ce466076b doc_id: 903813 cord_uid: lymnkl97 OBJECTIVE: To report the perioperative outcomes of 200 patients with gynecologic cancer who underwent surgery during the Novel Coronavirus Disease (COVID‐19) pandemic and the safety of surgical approach. METHODS: Data of patients operated between March 10 and May 20, 2020, were collected retrospectively. Data were statistically analyzed using IBM Statistical Package for the Social Sciences (SPSS) Statistics for Windows v. SP21.0. RESULTS: Data of 200 patients were included. Their mean age was 56 years. Of the patients, 54% (n=108), 27.5% (n=55), 12.5% (n=25), and 2% (n=4) were diagnosed as having endometrial, ovarian, cervical, and vulvar cancer, respectively. Of them, 98% underwent non‐emergent surgery. A minimally invasive surgical approach was used in 18%. Stage 1 cancer was found in 68% of patients. Surgeons reported COVID‐related changes in 10% of the cases. The rate of postoperative complications was 12%. Only two patients had cough and suspected pneumonic lesions on thoracic computed tomography postoperatively, but neither was positive for COVID‐19 on polymerase chain reaction testing. CONCLUSION: Based on the present findings, it is thought that gynecologic cancer surgery should continue during the COVID‐19 pandemic while adhering to the measures. Postponement or non‐surgical management should only be considered in patients with documented infection. Gynecologic cancer surgery should continue during the COVID‐19 pandemic while adhering to measures. Only 1% of patients developed COVID‐19‐related symptoms during the postoperative follow‐up period. The Novel Coronavirus Disease (COVID- 19) pandemic is a rapidly emerging situation with devastating consequences. To date, WHO 1 has reported more than 5 million positive cases and 300 000 deaths in 216 countries. It is clear that these numbers will continue to increase. Initial assumptions estimated that the pandemic has consumed healthcare resources; therefore, it has a significant impact on the healthcare services. Hospital bed, medical staff, intensive care unit (ICU), and mechanical ventilator capacity are now primarily occupied by COVID-19 patients in the majority of hospitals. 2 Worldwide, many hospitals are restricting non-emergent surgical procedures. Furthermore, government authorities and some medical societies have published recommendations and guidelines for curtailing or postponing cancer diagnostics, treatment, and/or surgery in order to reallocate resources to the treatment of COVID-19 patients and to save patients with cancer and healthcare staff from the Severe Acute Respiratory Syndrome Corona Virus-2 (SARS-CoV-2). 3 Postponing treatment for cancer can have significantly negative effects. A recent study 4 showed that there is a significant relationship between delay in surgery and reduced overall survival in patients with solid cancers. The researchers concluded that a surgical delay of more than 40 days is associated with poor outcome in patients with colon cancer. Similar findings have been reported in patients with cervical cancer in a nationwide analysis and concluded that "longer intervals between diagnosis and treatment are associated with poorer prognosis among cervical cancer patients". 5 were asked to provide data on general patient characteristics, co-morbidities, preoperative and postoperative disease stage, some blood parameters, surgical procedure, the postoperative follow-up process, and both preoperative and postoperative COVID-19-related data (symptoms/screening/testing). All human participants gave written/ verbal informed consent before the study began. As the proper use of resources is of great importance during the pandemic, the prevalence of COVID-19 and the caseload in all associated units were carefully evaluated and considered. In addition, careful attention was paid to reach a consensus with anesthesiologists and ICUs during planning. All patients scheduled for surgery were screened for symptoms of COVID-19 in the preoperative period. Most were hospitalized 24-48 hours preoperatively. Considering the importance of preoperative imaging in the management of gynecologic cancer, most of the patients had a thoracic chest X-ray or computed tomography (CT) scan. Only one companion was allowed and a no-visitors policy was implemented. All wore face masks during the hospital stay. On the day of surgery, patients were transferred directly to the operating room (OR), with a face mask, without stopping in any areas, in order to minimize exposure. Stretcher personnel wore personal protective equipment (PPE) and were trained to perform disinfection immediately after completion of each transfer. During induction of anesthesia and endotracheal intubation, only the most experienced team were in the room. All OR staff were required to practice enhanced droplet and contact precautions, including the use of an N95 respirator, eye protection, gown, and gloves. When a negative-pressure OR was not available, a high air exchange cycle rate (≥25 cycles h -1 ) was maintained for lower viral load. Equipment was minimized to those pieces most necessary for the procedure and transiting was limited. The most suitable procedure according to disease characteristics was performed. During the postoperative period, early recovery procedures and early discharge was encouraged. None of the patients or healthcare Data for 212 patients were collected, but 12 were excluded due to incomplete data. The mean patient age was 56 years (range 24-85 years). The most common type of gynecologic cancer was endometrial carcinoma (n=108 [54%]), followed by ovarian (n=55 had non-emergent surgery, whereas four had emergent surgery due to tumor rupture, bleeding, and bowel obstruction. Of the patients, 80% underwent open-route laparotomy, whereas a minimally invasive approach was performed in 18%. In 2% of the cases, laparoscopic surgery had to be converted to an open approach. Of the patients, 68% were stage 1 and 30% were stages 3-4. Type 1 hysterectomy ± bilateral salpingo-oophorectomy (BSO) without lymph node dissection (LND) was performed in 10% of the patients, most of which had low-risk early-stage endometrial carcinoma. Lymphadenectomy was added in 25% of the patients. Type 3 hysterectomy was performed in 7% of the patients, most of whom had cervical carcinoma. In the patients with disseminated ovarian tumors (49%), maximal cytoreduction was performed. Vulvectomy was performed in 2% of the patients. Lymphadenectomy was performed in 80% of the cases. Bowel resection and ileocolostomy was performed in 2.5%. Surgeons reported that they decided to change the surgical approach and/or radicality of surgery in 10% of the cases due to the pandemic. The Table 1 , and postoperative complications and COVID-19-specific effects are summarized in Table 2 . in addition to COVID-19, there is a risk of exposure to HBV, HCV, and HIV. The present findings show that only 1% of asymptomatic patients with gynecologic cancer who underwent surgery were positive for COVID-19 after surgery. These preliminary data must be confirmed by other researchers, which it is expected will occur as the pandemic continues to spread worldwide. Fear of COVID-19 infection and lack of knowledge about the transmission might be considered significant factors that affect physician's decisions regarding treatment. Nevertheless, in order to prevent hospital-acquired COVID-19 among healthcare workers and patients, preoperative thoracic CT, PCR, antibody testing, 14-day quarantine, performing surgery in negative pressure ORs, providing the necessary PPE, and early discharge policies should be instituted. In the light of the findings of the present retrospective multicenter study, it is thought that surgical treatment of patients with gynecologic cancers should not be canceled or postponed during the COVID-19 pandemic. Gynecologic cancer surgery must remain the principal treatment and should be the last treatment modality to be modified or canceled/postponed. PD, HD, and MD: concept and design of study, manuscript preparation, editing and review; PD and MD: data analysis and interpretation; PD: statistical analysis. All authors performed data acquisition. Coronavirus disease Medical Treatment Expert Group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China Cancer surgery in a time of COVID-19: Many questions, few certainties Duchalais E et al Impact of delay to surgery on survival in stage I-III colon cancer Effect of time interval from diagnosis to treatment for cervical cancer on survival: A nationwide cohort study COVID-19 Global pandemic: Options for management of gynecologic cancers Management of cancer surgery cases during the COVID-19 pandemic: Considerations Fewer cancer diagnoses during the COVID-19 epidemic in the Netherlands Collateral damage: The impact on outcomes from cancer surgery of the COVID-19 pandemic [published online ahead of print Elective surgery cancellations due to the COVID-19 pandemic: Global predictive modelling to inform surgical recovery plans Elective Case Triage Guidelines for Surgical Care Gynecology COVID-19 Communique: Surgical Considerations for Gynecologic Oncologists During the COVID-19 Pandemic Do critical care units play a role in the management of gynaecological oncology patients? The contribution of gynaecologic oncologist in running critical care units The impact of COVID-19 on the provision of donor hematopoietic stem cell products worldwide: collateral damage Cancer patients in SARS-CoV-2 infection: A nationwide analysis in China Clinical Characteristics of COVID-19 after gynecologic oncology surgery in three women: A retrospective review of medical records Performing abdominal surgery during the COVID-19 epidemic in Wuhan, China: A single-centred, retrospective, observational study Cancer surgery during the Covid-19 pandemic in Turkey Incidental findings suggestive of COVID-19 in asymptomatic patients undergoing nuclear medicine procedures in a high-prevalence region global pandemic: Options for management of gynecologic cancers. The experience in surgical management of ovarian cancer in the second highest affected Italian region Global guidance for surgical care during the COVID-19 pandemic Molecular and serological investigation of 2019-nCoV infected patients: Implication of multiple shedding routes Detecting hepatitis B virus in surgical smoke emitted during laparoscopic surgery Minimally invasive surgery and the novel coronavirus outbreak: Lessons learned in China and Italy The authors have no conflicts of interest.